Displaying drugs 476 - 500 of 7478 in total
Niraparib
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 CYP1A2 Inducers ... Cytochrome P-450 Enzyme Inducers ... Cytochrome P-450 CYP1A2 Inducers (weak) ... P-glycoprotein substrates with a Narrow Therapeutic Index …
Alfuzosin
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... P-glycoprotein substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Chlordiazepoxide
An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
Approved
Illicit
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Treprostinil
Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP2C9 Substrates …
Flurandrenolide
A corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive. (From Martindale, The Extra Pharmacopoeia, 30th ed, p733)
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Physostigmine
A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.
Approved
Investigational
Perflubutane
Perflubutane has been used in trials studying the diagnostic of Liver Mass, Liver Diseases, Liver Metastasis, Portal Hypertension, and Peripheral Artery Disease. It is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing; currently the leading procedure for detecting coronary heart disease.
Approved
Investigational
Parthenolide
Parthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.
Approved
Investigational
Pramiracetam
Pramiracetam has been previously approved in some eastern European countries under the brand names Pramistar, Neupramir, and Remen. It was also previously approved in the United States with orphan drug designation . Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive...
Approved
Methysergide
An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Methyltestosterone
A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2B6 Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Disopyramide
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Baricitinib
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... P-glycoprotein substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... P-glycoprotein substrates with a Narrow Therapeutic Index …
Cocaine
An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of...
Approved
Illicit
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 Enzyme Inhibitors …
Dicoumarol
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index …
Tolcapone
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Approved
Withdrawn
Matched Categories: … Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Cinoxacin
Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
Approved
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
Macimorelin
Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Lidoflazine
Approved
Experimental
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Oxycodone
Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone...
Approved
Illicit
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2D6 Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates …
Fentanyl
Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like morphine and oxycodone.
Fentanyl's high potency has also...
Approved
Illicit
Investigational
Vet approved
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A7 Substrates …
Hepatitis B Vaccine (Recombinant)
Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada.
The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis...
Approved
Withdrawn
Gallium Ga-68 gozetotide
Gallium (Ga) 68 prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and assess prostate-specific membrane antigen (PSMA)-positive lesions in adult men with prostate cancer during positron emission tomography (PET). Prostate cancer is one of the most commonly diagnosed cancers among men in Western countries...
Approved
Nabumetone
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP2C9 Substrates …
Displaying drugs 476 - 500 of 7478 in total